2 febrero 2010 | EN
Pharmaceutical company GlaxoSmithKline (GSK) has set an example to other drug companies by making its database of potential malaria drugs public, says a Nature editorial.
The move last month (January), provides access to data on 13,500 malaria drug candidates and marks an unprecedented open attitude to data sharing from big pharma (see Glaxo to share malaria drug data).
The editorial applauds GSK's chief executive, Andrew Witty, for showing leadership in this attempt to re-engage with the neglected diseases that primarily affect developing countries. It suggests that more drug companies should embrace a similar attitude towards these diseases, as they present a "low risk area" for experimenting with open data.
Other institutions also have a role to play, argues the editorial.
Academic organisations must provide the infrastructure for archiving open data, and universities should support research that can develop drug leads such as those presented by GSK.
And both should be more open. The editorial accuses academics and their institutions of being among the "worst offenders" in terms of "hogging intellectual property", and concludes by suggesting they follow GSK's lead and allow royalty-free use of technologies for good causes.
Todos los comentarios están sujetos a revisión. Nos reservamos el derecho de editar los comentarios que contengan un lenguaje inapropiado o inadecuado. SciDev.Net mantiene los derechos de autor de todo el material que se publica en el portal. Por favor lea las condiciones de uso para más detalles.
Todo el material de SciDev.Net se puede reproducir gratuitamente siempre que se de crédito a la fuente y al autor. Para más detalles ver Creative commons.